Table 3. Inpatient medication administrations among hospitalizations with COVID-19 diagnosis stratified by ICU stays and age category, February 20, 2020-September 30, 2021*.
| Hospitalizations with COVID-19 diagnosis (N = 2,186) | Hospitalizations with multisystem Inflammatory syndrome diagnosis (N = 395) | Hospitalizations with COVID-19 diagnosis AND ICU admission (N = 917) | Hospitalizations with COVID-19 diagnosis among patients less than 12 years of age (N = 1,306) | Hospitalizations with COVID-19 diagnosis among patients 12–17 years of age (N = 880) | |
|---|---|---|---|---|---|
| % | % | % | % | % | |
| Potential COVID-19 treatments† | |||||
| Remdesivir | 13.3% | 4.8% | 22.9% | 5.7% | 24.4% |
| Tocilizumab | 0.4% | 0.8% | 0.8% | 0.1% | 0.8% |
| Sarilumab | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Eculizumab | 0.0% | 0.0% | 0.1% | 0.0% | 0.1% |
| Methylprednisolone | 34.4% | 75.1% | 40.7% | 43.5% | 24.8% |
| Lopinavir / Ritonavir | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Norepinephrine | 1.1% | 8.4% | 2.4% | 0.8% | 1.7% |
| Dexamethasone | 24.6% | 14.9% | 33.0% | 16.9% | 36.0% |
| Remdesivir and Dexamethasone§ | 11.3% | 3.8% | 19.4% | 3.9% | 22.2% |
| Baricitinib | 0.3% | 0.3% | 0.4% | 0.0% | 0.8% |
| Baricitinib and Remdesivir | 0.2% | 0.0% | 0.3% | 0.0% | 0.6% |
| Bamlanivimab | 0.0% | 0.3% | 0.1% | 0.0% | 0.1% |
| Casirivimab / Imdevimab | 0.1% | 0.0% | 0.1% | 0.0% | 0.2% |
| Bamlanivimab and Etesevimab | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Antibiotics† | |||||
| Any Antibiotic use | 49.9% | 68.1% | 59.7% | 47.2% | 53.9% |
| Azithromycin | 13.8% | 12.9% | 18.3% | 9.4% | 20.2% |
| Doxycycline | 1.0% | 8.9% | 1.5% | 0.7% | 1.4% |
| Antithrombotic medications† | |||||
| Low molecular weight heparin | 17.3% | 33.7% | 31.2% | 5.8% | 34.4% |
| Tissue plasminogen activator | 2.0% | 5.8% | 4.1% | 2.2% | 1.6% |
| Vitamin K antagonists | 0.0% | 0.0% | 0.1% | 0.1% | 0.0% |
| Factor Xa inhibitors | 0.2% | 0.3% | 0.4% | 0.0% | 0.5% |
| Thrombin inhibitors | 2.2% | 6.1% | 4.6% | 2.3% | 1.9% |
| Anti-platelet therapy | 6.3% | 51.4% | 10.8% | 6.9% | 5.5% |
| Immune globulin (IVIg) | |||||
| Immune globulin (IVIg) | 6.6% | 67.1% | 11.8% | 7.5% | 5.2% |
*Includes discharges for final billed patients only. The analysis does not include inpatient stays for patients still admitted or not completely coded by the data pull date.
†We defined administration of potential COVID-19 treatments and anti-thrombotic medications by National Drug Codes (NDC) and text string searches for generic and brand name.